Sign in

Publications

Search in 13066 publications:

Reset RSS
Time frame
11585 Publication(s)
Nov 27, 2021
Die gezielte Untersuchung des Ellbogens - die wichtigsten Tests für den klinischen Alltag
Olach M, Spross C. Die gezielte Untersuchung des Ellbogens - die wichtigsten Tests für den klinischen Alltag. Rheuma Schweiz 2021
Nov 27, 2021
Die gezielte Untersuchung des Ellbogens - die wichtigsten Tests für den klinischen Alltag
Nov 27, 2021

Rheuma Schweiz 2021

Olach Martin, Spross Christian

more
Nov 27, 2021
HCV disease burden and population segments in Switzerland
Bihl F, Semmo N, Semela D, Scheidegger C, Razavi H, Negro F, Mullhaupt B, Lavanchy D, Dufour J, Castro Batänjer E, Bruggmann P, Blach S. HCV disease burden and population segments in Switzerland. Liver Int 2021
Nov 27, 2021
HCV disease burden and population segments in Switzerland
Nov 27, 2021

Liver Int 2021

Bihl Florian, Semmo Nasser, Semela David, Scheidegger Claude, Razavi Homie, Negro Francesco, Mullhaupt Beat, Lavanchy Daniel, Dufour Jean-François, Castro Batänjer Erika, Bruggmann Philip, Blach Sarah

more
Nov 26, 2021
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings
Vogl U, Mottet N, Padhani A, Roach M, Rubin M, Sartor O, Small E, Smith M, Soule H, Sydes M, Tombal B, Omlin A, Gillessen S, James N, Halabi S, Beer T, Davis I, Shore N, Sweeney C, Ost P, Attard G, Bossi A, de Bono J, Drake C, Efstathiou E, Fanti S, Fizazi K, APCCC 2019 expert panel. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. Eur J Cancer 2021; 160:24-60.
Nov 26, 2021
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings
Nov 26, 2021

Eur J Cancer 2021; 160:24-60

Vogl Ursula M, Mottet Nicolas, Padhani Anwar R, Roach Mack, Rubin Mark, Sartor Oliver, Small Eric, Smith Matthew R, Soule Howard, Sydes Matthew R, Tombal Bertrand, Omlin Aurelius, Gillessen Silke, James Nicolas, Halabi Susan, Beer Tomasz M, Davis Ian D, Shore Neal D, Sweeney Christopher J, Ost Piet, Attard Gerhardt, Bossi Alberto, de Bono Johann, Drake Charles G, Efstathiou Eleni, Fanti Stefano, Fizazi Karim, APCCC 2019 expert panel

more
Nov 26, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo R, Han J, Dafni U, Cho B, Yeo C, Nadal E, Carcereny E, de Castro J, Sala M, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi S, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres J, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R, Peters S, ETOP 10-16 BOOSTER Collaborators. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Ann Oncol 2021; 33:181-192.
Nov 26, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Nov 26, 2021

Ann Oncol 2021; 33:181-192

Soo R A, Han J-Y, Dafni U, Cho B C, Yeo C M, Nadal E, Carcereny E, de Castro J, Sala M A, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi S M S, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres J-M, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R A, Peters S, ETOP 10-16 BOOSTER Collaborators

more
Nov 25, 2021
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
Müller V, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T, Hoffmann O, Rübner M, Huober J, Banys-Paluchowski M, Friedl T, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, DETECT study group. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open 2021; 6:100299.
Nov 25, 2021
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
Nov 25, 2021

ESMO Open 2021; 6:100299

Müller V, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T, Hoffmann O, Rübner M, Huober Jens, Banys-Paluchowski M, Friedl T W P, Fasching P A, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, DETECT study group

more
Nov 24, 2021
Extra-axial chordoma within a tendon of the hand.
Greminger M, Bode-Lesniewska B, Fuchs B. Extra-axial chordoma within a tendon of the hand. J Hand Surg Eur Vol 2021; 47:530-531.
Nov 24, 2021
Extra-axial chordoma within a tendon of the hand.
Nov 24, 2021

J Hand Surg Eur Vol 2021; 47:530-531

Greminger Martina, Bode-Lesniewska Beata, Fuchs Bruno

more
Nov 24, 2021
Diagnostik und Behandlung des akuten Abdomens
Sinz S, Schmied B, Ukegjini K. Diagnostik und Behandlung des akuten Abdomens. Swiss Med Forum 2021; 21:803-809.
Nov 24, 2021
Diagnostik und Behandlung des akuten Abdomens
Nov 24, 2021

Swiss Med Forum 2021; 21:803-809

Sinz Stefanie, Schmied Bruno, Ukegjini Kristjan

more
Nov 24, 2021
Evolution of COVID-19 mortality over time: results from the Swiss hospital surveillance system (CH-SUR)
Roelens M, Schreiber P, Sommerstein R, Troillet N, Tschudin-Sutter S, Vetter P, Bernhard-Stirnemann S, Corti N, Gaudenz R, Marschall J, Nussbaumer-Ochsner Y, Senn L, Vuichard-Gysin D, Zimmermann P, Zucol F, Iten A, Riedel T, Niederer-Loher A, Martin A, Friker B, Sousa F, Thiabaud A, Vidondo B, Buchter V, Gardiol C, Vonlanthen J, Balmelli C, Battegay M, Christoph B, Buettcher M, Cusini A, Flury D, Heininger U, Keiser O. Evolution of COVID-19 mortality over time: results from the Swiss hospital surveillance system (CH-SUR). Swiss Med Wkly 2021; 151:w30105.
Nov 24, 2021
Evolution of COVID-19 mortality over time: results from the Swiss hospital surveillance system (CH-SUR)
Nov 24, 2021

Swiss Med Wkly 2021; 151:w30105

Roelens Maroussia, Schreiber Peter W, Sommerstein Rami, Troillet Nicolas, Tschudin-Sutter Sarah, Vetter Pauline, Bernhard-Stirnemann Sara, Corti Natascia, Gaudenz Roman, Marschall Jonas, Nussbaumer-Ochsner Yvonne, Senn Laurence, Vuichard-Gysin Danielle, Zimmermann Petra, Zucol Franziska, Iten Anne, Riedel Thomas, Niederer-Loher Anita, Martin Alexis, Friker Brian, Sousa Filipe Maximiano, Thiabaud Amaury, Vidondo Beatriz, Buchter Valentin, Gardiol Céline, Vonlanthen Jasmin, Balmelli Carlo, Battegay Manuel, Christoph Berger, Buettcher Michael, Cusini Alexia, Flury Domenica, Heininger Ulrich, Keiser Olivia

more
Nov 24, 2021
Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper.
Zuberbier T, Dörr T, Aberer W, Alvaro-Lozano M, Angier E, Arasi S, Arshad H, Ballmer-Weber B, Bartra J, Beck L, Bégin P, Bindslev-Jensen C, Bislimovska J, Bousquet J, Brockow K, Bush A, Cianferoni A, Cork M, Custovic A, Darsow U, de Jong N, Deleanu D, Del Giacco S, Deschildre A, Dunn Galvin A, Ebisawa M, Fernández-Rivas M, Ferrer M, Fiocchi A, Gerth van Wijk R, Gotua M, Grimshaw K, Grünhagen J, Heffler E, Hide M, Hoffmann-Sommergruber K, Incorvaia C, Janson C, John S, Jones C, Jutel M, Katoh N, Kendziora B, Kinaciyan T, Knol E, Kurbacheva O, Lau S, Loh R, Lombardi C, Mäkelä M, Marchisotto M, Makris M, Maurer M, Meyer R, Mijakoski D, Minov J, Mullol J, Nilsson C, Nowak-Wegrzyn A, Nwaru B, Odemyr M, Pajno G, Paudel S, Papadopoulos N, Renz H, Ricci G, Ring J, Rogala B, Sampson H, Senna G, Sitkauskiene B, Smith P, Stevanovic K, Stoleski S, Szajewska H, Tanaka A, Todo-Bom A, Topal F, Valovirta E, Van Ree R, Venter C, Wöhrl S, Wong G, Zhao Z, Worm M. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper. Allergy 2021; 77:1736-1750.
Nov 24, 2021
Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper.
Nov 24, 2021

Allergy 2021; 77:1736-1750

Zuberbier Torsten, Dörr Tamara, Aberer Werner, Alvaro-Lozano Montserrat, Angier Elizabeth, Arasi Stefania, Arshad Hasan, Ballmer-Weber Barbara, Bartra Joan, Beck Lisa, Bégin Philippe, Bindslev-Jensen Carsten, Bislimovska Jovanka, Bousquet Jean, Brockow Knut, Bush Andrew, Cianferoni Antonella, Cork Michael J, Custovic Adnan, Darsow Ulf, de Jong Nicolette, Deleanu Diana, Del Giacco Stefano, Deschildre Antoine, Dunn Galvin Audrey, Ebisawa Motohiro, Fernández-Rivas Montserrat, Ferrer Marta, Fiocchi Alessandro, Gerth van Wijk Roy, Gotua Maia, Grimshaw Kate E C, Grünhagen Josefine, Heffler Enrico, Hide Michihiro, Hoffmann-Sommergruber Karin, Incorvaia Cristoforo, Janson Christer, John Swen Malte, Jones Carla, Jutel Marek, Katoh Norito, Kendziora Benjamin, Kinaciyan Tamar, Knol Edward, Kurbacheva Oksana, Lau Susanne, Loh Richard, Lombardi Carlo, Mäkelä Mika, Marchisotto Mary Jane, Makris Michael, Maurer Marcus, Meyer Rosan, Mijakoski Dragan, Minov Jordan, Mullol Joaquim, Nilsson Caroline, Nowak-Wegrzyn Anna, Nwaru Bright I, Odemyr Mikela, Pajno Giovanni Battista, Paudel Sushil, Papadopoulos Nikolaos G, Renz Harald, Ricci Giampaolo, Ring Johannes, Rogala Barbara, Sampson Hugh A, Senna Gianenrico, Sitkauskiene Brigita, Smith Peter Kenneth, Stevanovic Katarina, Stoleski Sasho, Szajewska Hania, Tanaka Akio, Todo-Bom Ana, Topal Fatih Alexander, Valovirta Erkka, Van Ree Ronald, Venter Carina, Wöhrl Stefan, Wong George K C, Zhao Zuotao, Worm Margitta

more
Nov 22, 2021
Digital SARS-CoV-2 Detection Among Hospital Employees: Participatory Surveillance Study
Leal-Neto O, Kahlert C, Vernazza P, Kuster S, Babouee Flury B, Albrich W, Sumer J, Flury D, Schlegel M, Egger T, Kohler P. Digital SARS-CoV-2 Detection Among Hospital Employees: Participatory Surveillance Study. JMIR Public Health Surveill 2021; 7:e33576.
Nov 22, 2021
Digital SARS-CoV-2 Detection Among Hospital Employees: Participatory Surveillance Study
Nov 22, 2021

JMIR Public Health Surveill 2021; 7:e33576

Leal-Neto Onicio, Kahlert Christian, Vernazza Pietro, Kuster Stefan, Babouee Flury Baharak, Albrich Werner, Sumer Johannes, Flury Domenica, Schlegel Matthias, Egger Thomas, Kohler Philipp

more
Nov 20, 2021
Neues Integriertes psychosomatisches Versorgungsmodell am Kantonsspital St.Gallen (K+L-Dienst)
Studer K, Hämmerli Keller K, Schmid D. Neues Integriertes psychosomatisches Versorgungsmodell am Kantonsspital St.Gallen (K+L-Dienst). Swiss Arch Neurol Psychiatr Psychother 2021; 172:201-202.
Nov 20, 2021
Neues Integriertes psychosomatisches Versorgungsmodell am Kantonsspital St.Gallen (K+L-Dienst)
Nov 20, 2021

Swiss Arch Neurol Psychiatr Psychother 2021; 172:201-202

Studer Karl, Hämmerli Keller Katja, Schmid Dagmar

more
Nov 18, 2021
Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study
Nanchen D, Reichert N, Rossi M, Crljenica C, Mueller C, Mach F, Koskinas K, Rickli H, Bilz S, Carballo D, Sudano I. Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study. Adv Ther 2021; 39:504-517.
Nov 18, 2021
Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study
Nov 18, 2021

Adv Ther 2021; 39:504-517

Nanchen David, Reichert Nina, Rossi Mariagrazia, Crljenica Carmela, Mueller Christian, Mach François, Koskinas Konstantinos C, Rickli Hans, Bilz Stefan, Carballo David, Sudano Isabella

more
Nov 18, 2021
Decreasing incidence and determinants of Bacterial Pneumonia in people with HIV: The Swiss HIV Cohort Study
Balakrishna S, Günthard H, Battegay M, Bernasconi E, Schmid P, Cavassini M, Calmy A, Hauser C, Furrer H, Scherrer A, Kusejko K, Roth J, Kachalov V, Wolfensberger A, Kouyos R. Decreasing incidence and determinants of Bacterial Pneumonia in people with HIV: The Swiss HIV Cohort Study. J Infect Dis 2021
Nov 18, 2021
Decreasing incidence and determinants of Bacterial Pneumonia in people with HIV: The Swiss HIV Cohort Study
Nov 18, 2021

J Infect Dis 2021

Balakrishna Suraj, Günthard Huldrych F, Battegay Manuel, Bernasconi Enos, Schmid Patrick, Cavassini Matthias, Calmy Alexandra, Hauser Christoph, Furrer Hansjakob, Scherrer Alexandra U, Kusejko Katharina, Roth Jan A, Kachalov Viacheslav, Wolfensberger Aline, Kouyos Roger D

more
Nov 17, 2021
Variations in Radioiodine Therapy in Europe - Decision-Making after Total Thyroidectomy
Forrer F, Zerdoud S, Vrachimis A, Petranovic Ovčaričekj P, Mihailovic J, Luster M, Iakovou I, Hoffmann M, Giovanella L, Maas O, Fischer G, Putora P. Variations in Radioiodine Therapy in Europe - Decision-Making after Total Thyroidectomy. Oncology 2021
Nov 17, 2021
Variations in Radioiodine Therapy in Europe - Decision-Making after Total Thyroidectomy
Nov 17, 2021

Oncology 2021

Forrer Flavio, Zerdoud Slimane, Vrachimis Alexis, Petranovic Ovčaričekj Petra, Mihailovic Jasna, Luster Markus, Iakovou Ioannis, Hoffmann Martha, Giovanella Luca, Maas Ole, Fischer Galina, Putora Paul Martin

more
Nov 17, 2021
Mid-term outcomes following transfemoral revision of total hip arthroplasty for Vancouver B2/B3 periprosthetic fractures
Schöfl T, Calek A, Zdravkovic V, Zurmühle P, Ladurner A. Mid-term outcomes following transfemoral revision of total hip arthroplasty for Vancouver B2/B3 periprosthetic fractures. Injury 2021
Nov 17, 2021
Mid-term outcomes following transfemoral revision of total hip arthroplasty for Vancouver B2/B3 periprosthetic fractures
Nov 17, 2021

Injury 2021

Schöfl Thomas, Calek Anna-Katharina, Zdravkovic Vilijam, Zurmühle Pia, Ladurner Andreas

more
Nov 17, 2021
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Schneeweiss A, Blohmer J, Fasching P, Solbach C, Schmutzler R, Huober J, Rhiem K, Nekljudova V, Lübbe K, Loibl S, Jackisch C, Untch M, Link T, Michel L, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, GBG and AGO-B. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Eur J Cancer 2021
Nov 17, 2021
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Nov 17, 2021

Eur J Cancer 2021

Schneeweiss Andreas, Blohmer Jens-Uwe, Fasching Peter A, Solbach Christine, Schmutzler Rita K, Huober Jens, Rhiem Kerstin, Nekljudova Valentina, Lübbe Kristina, Loibl Sibylle, Jackisch Christian, Untch Michael, Link Theresa, Michel Laura L, Möbus Volker, Tesch Hans, Klare Peter, Hahnen Eric, Denkert Carsten, Kast Karin, Pohl-Rescigno Esther, Hanusch Claus, GBG and AGO-B

more
Nov 17, 2021
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus E, Ostad-Saffari E, Scalori A, Oh Y, Tole S, Chai A, Pulley J, Lacey S, Sandborn W, HICKORY Study Group. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol 2021; 7:128-140.
Nov 17, 2021
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Nov 17, 2021

Lancet Gastroenterol Hepatol 2021; 7:128-140

Peyrin-Biroulet Laurent, Hart Ailsa, Bossuyt Peter, Long Millie, Allez Matthieu, Juillerat Pascal, Armuzzi Alessandro, Loftus Edward V, Ostad-Saffari Elham, Scalori Astrid, Oh Young S, Tole Swati, Chai Akiko, Pulley Jennifer, Lacey Stuart, Sandborn William J, HICKORY Study Group

more
Nov 17, 2021
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S, Colombel J, Lukas M, Gisbert J, D'Haens G, Hayee B, Panaccione R, Kim H, Reinisch W, Tyrrell H, Oh Y, Tole S, Chai A, Chamberlain-James K, Tang M, Schreiber S, GARDENIA Study Group. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol 2021; 7:118-127.
Nov 17, 2021
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Nov 17, 2021

Lancet Gastroenterol Hepatol 2021; 7:118-127

Danese Silvio, Colombel Jean-Frédéric, Lukas Milan, Gisbert Javier P, D'Haens Geert, Hayee Bu'hussain, Panaccione Remo, Kim Hyun-Soo, Reinisch Walter, Tyrrell Helen, Oh Young S, Tole Swati, Chai Akiko, Chamberlain-James Kirsten, Tang Meina Tao, Schreiber Stefan, GARDENIA Study Group

more
Nov 15, 2021
Author Reply to "Intravenous thrombolysis in patients taking direct oral anticoagulants (European stroke organisation intravenous thrombolysis guidelines comment).
De Marchis G, Turc G, Whiteley W, Tsivgoulis G. Author Reply to "Intravenous thrombolysis in patients taking direct oral anticoagulants (European stroke organisation intravenous thrombolysis guidelines comment). Eur Stroke J 2021; 6:447-449.
Nov 15, 2021
Author Reply to "Intravenous thrombolysis in patients taking direct oral anticoagulants (European stroke organisation intravenous thrombolysis guidelines comment).
Nov 15, 2021

Eur Stroke J 2021; 6:447-449

De Marchis Gian Marco, Turc Guillaume, Whiteley William, Tsivgoulis Georgios

more
Nov 15, 2021
Pros and Cons of Early and Very Early Surgery for Traumatic Central Cord Syndrome with Spinal Stenosis: Literature Review and Case Report.
Hildebrandt G, Joswig H, Stienen M, Bratelj D. Pros and Cons of Early and Very Early Surgery for Traumatic Central Cord Syndrome with Spinal Stenosis: Literature Review and Case Report. J Neurol Surg A Cent Eur Neurosurg 2021; 83:57-65.
Nov 15, 2021
Pros and Cons of Early and Very Early Surgery for Traumatic Central Cord Syndrome with Spinal Stenosis: Literature Review and Case Report.
Nov 15, 2021

J Neurol Surg A Cent Eur Neurosurg 2021; 83:57-65

Hildebrandt Gerhard, Joswig Holger, Stienen Martin Nikolaus, Bratelj Denis

more

We use cookies and tracking technologies according to our privacy policy to provide you with the best possible web experience. To the privacy policy